OBSIDIAN THERAPEUTICS, INC. Retained Earnings
OBSIDIAN THERAPEUTICS, INC. (OBX) had Retained Earnings of $341.43 million as of 2026-06-30, per its S-1 filed 2026-08-28.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-28
- 2026-06-30: Retained Earnings (Accumulated Deficit) $341.43M; Retained Earnings (Accumulated Deficit) as first filed $0.00.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $295.94M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) $195.33M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | $341.43M S-1 · filed 2026-08-28 | $0.00 10-Q · filed 2026-08-14 |
| 2025-12-31 | $295.94M S-1 · filed 2026-08-28 | |
| 2024-12-31 | $195.33M S-1 · filed 2026-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |